Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

References

• Siegel R DeSantis C Virgo K Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 2012 62 4 220 241 22700443
   PubMed Web of Science ®Google Scholar
• Kim WY Kaelin WG Role of VHL gene mutation in human cancer J Clin Oncol 2004 22 24 4991 5004 15611513
   PubMed Web of Science ®Google Scholar
• Wiesener MS Münchenhagen PM Berger I Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas Cancer Res 2001 61 13 5215 5222 11431362
   PubMed Web of Science ®Google Scholar
• Gnarra JR Tory K Weng Y Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 1994 7 1 85 90 7915601
   PubMed Web of Science ®Google Scholar
• Shuin T Kondo K Torigoe S Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 1994 54 11 2852 2855 8187067
   PubMed Web of Science ®Google Scholar
• Carmeliet P VEGF as a key mediator of angiogenesis in cancer Oncology 2005 69 Suppl 3 4 10 16301830
   PubMed Web of Science ®Google Scholar
• Motzer RJ Russo P Systemic therapy for renal cell carcinoma J Urol 2000 163 2 408 417 10647643
   PubMed Web of Science ®Google Scholar
• Bukowski RM Cytokine therapy for metastatic renal cell carcinoma Semin Urol Oncol 2001 19 2 148 154 11354535
   PubMedGoogle Scholar
• Motzer RJ Mazumdar M Bacik J Berg W Amsterdam A Ferrara J Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 8 1999 17 8 2530 2540 10561319
   PubMed Web of Science ®Google Scholar
• Rini BI Halabi S Rosenberg JE Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 2008 26 33 5422 5428 18936475
   PubMed Web of Science ®Google Scholar
• Rini BI Halabi S Rosenberg JE Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 2010 28 13 2137 2143 20368558
   PubMed Web of Science ®Google Scholar
• Escudier B Pluzanska A Koralewski P AVOREN Trial investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 370 9605 2103 2111 18156031
   PubMed Web of Science ®Google Scholar
• Escudier B Bellmunt J Négrier S Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 2010 28 13 2144 2150 20368553
   PubMed Web of Science ®Google Scholar
• Motzer RJ Hutson TE Tomczak P Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 2007 356 2 115 124 17215529
   PubMed Web of Science ®Google Scholar
• Motzer RJ Hutson TE Tomczak P Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 2009 27 22 3584 3590 19487381
   PubMed Web of Science ®Google Scholar
• Sternberg CN Davis ID Mardiak J Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 2010 28 6 1061 1068 20100962
   PubMed Web of Science ®Google Scholar
• Rini BI Escudier B Tomczak P Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 2011 378 9807 1931 1939 22056247
   PubMed Web of Science ®Google Scholar
• Escudier B Eisen T Stadler WM Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 356 2 125 134 17215530
   PubMed Web of Science ®Google Scholar
• Escudier B Eisen T Stadler WM Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 2009 27 20 3312 3318 19451442
   PubMed Web of Science ®Google Scholar
• Hudes G Carducci M Tomczak P Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 2007 356 22: 2271 2281 17538086
   PubMed Web of Science ®Google Scholar
• Motzer RJ Escudier B Oudard S RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 2008 372 9637 449 456 18653228
   PubMed Web of Science ®Google Scholar
• Motzer RJ Escudier B Oudard S RECORD-1 Study Group Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 2010 116 18 4256 4265 20549832
   PubMed Web of Science ®Google Scholar
• Eskens FA de Jonge MJ Bhargava P Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors Clin Cancer Res 2011 17 22 7156 7163 21976547
   PubMed Web of Science ®Google Scholar
• Nosov DA Esteves B Lipatov ON Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma J Clin Oncol 2012 30 14 1678 1685 22493422
   PubMed Web of Science ®Google Scholar
• Motzer RJ Nosov D Eisen T Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial J Clin Oncol 2012 30 Suppl Abstr 4501
   Google Scholar
• Eisen T Sternberg CN Detailed comparison of the safety of tivozanib hydrochloride versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial European Society of Medical Oncology 2012 Congress Abstract 795PD
   Google Scholar
• Kabbinavar FF Srinivas S Hauke RJ Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) J Clin Oncol 2011 29 Suppl Abstr 4549
   Google Scholar
• Hutson TE Rathmell K Hudes GR A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC) J Clin Oncol 2012 30 Suppl Abstr TPS4686
   Google Scholar
• Robinson MO Lin J Feng B Correlation of a tivozanib response biomarker identified in a preclinical model with clinical activity in a phase II study in renal cell carcinoma (RCC) J Clin Oncol 2010 28 Suppl Abstr e13564
   Google Scholar
• Pfizer A study in patients with non-small cell lung cancer testing if erlotinib plus SU011248 (sunitinib) is better than erlotinib alone (SUN1058) In: ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2011 [updated August 26, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00265317. NLM identifier: NCT00265317Accessed August 1, 2011
   Google Scholar
• Escudier BJ Porta C Bono P Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) – PISCES study, NCT 01064310 J Clin Oncol 2012 30 Suppl Abstr CRA4502
   Web of Science ®Google Scholar
• AVEO Oncology AVEO Reports Second Quarter 2012 Financial Results [press release] Cambridge, MA AVEO Oncology 2012 Available from: http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=;irol-newsArticle&ID=;1721417&highlight= Accessed November 15, 2012
   Google Scholar